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Introduction: Patients with severe sepsis often present with concurrent coagulopathy, microcirculatory failure and
evidence of vascular endothelial activation and damage. Given the critical role of the endothelium in balancing
hemostasis, we investigated single-point associations between whole blood coagulopathy by thrombelastography
(TEG) and plasma/serum markers of endothelial activation and damage in patients with severe sepsis.
Methods: A post-hoc multicenter prospective observational study in a subgroup of 184 patients from the Scandinavian
Starch for Severe Sepsis/Septic Shock (6S) Trial. Study patients were admitted to two Danish intensive care units.
Inclusion criteria were severe sepsis, pre-intervention whole blood TEG measurement and a plasma/serum research
sample available from baseline (pre-intervention) for analysis of endothelial-derived biomarkers. Endothelial-derived
biomarkers were measured in plasma/serum by enzyme-linked immunosorbent assay (syndecan-1, thrombomodulin,
protein C (PC), tissue-type plasminogen activator and plasminogen activator inhibitor-1). Pre-intervention TEG,
functional fibrinogen (FF) and laboratory and clinical data, including mortality, were retrieved from the trial database.
Results: Most patients presented with septic shock (86%) and pulmonary (60%) or abdominal (30%) focus of infection.
The median (IQR) age was 67 years (59 to 75), and 55% were males. The median SOFA and SAPS II scores were 8
(6 to 10) and 56 (41 to 68), respectively, with 7-, 28- and 90-day mortality rates being 21%, 39% and 53%, respectively.
Pre-intervention (before treatment with different fluids), TEG reaction (R)-time, angle and maximum amplitude (MA) and
FF MA all correlated with syndecan-1, thrombomodulin and PC levels. By multivariate linear regression analyses, higher
syndecan-1 and lower PC were independently associated with TEG and FF hypocoagulability at the same time-point: 100
ng/ml higher syndecan-1 predicted 0.64 minutes higher R-time (SE 0.25), 1.78 mm lower TEG MA (SE 0.87) and 0.84 mm
lower FF MA (SE 0.42; all P <0.05), and 10% lower protein C predicted 1.24 mm lower TEG MA (SE 0.31).
Conclusions: In our cohort of patients with severe sepsis, higher circulating levels of biomarkers of mainly endothelial
damage were independently associated with hypocoagulability assessed by TEG and FF. Endothelial damage is intimately
linked to coagulopathy in severe sepsis.
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Sepsis coagulopathy evolves from initial activation of coagu-
lation and fibrinolysis followed by late fibrinolytic shutdown
and exhaustion of the natural anticoagulant systems [1], the
latter mainly due to progressive endothelial disruption and
damage [2-6]. Though patients with severe sepsis display
evidence of varying degrees of coagulopathy with low or
declining platelet count, low coagulation factor and fibrino-
gen levels and high or increasing D-dimer level, these con-
ventional coagulation parameters do not reveal functional
whole blood hemostasis, including changes in fibrinolysis
and platelet (dys)function [2,6-10]. In contrast, viscoelastic
hemostatic whole blood tests like thrombelastography (TEG®,
Hemoscope-Hemonetics, Niles, IL, US) and rotation throm-
boelastometry (ROTEM®, TEM Inc., Durham, NC, US) [11]
display functional hemostasis in whole blood, including
fibrinolysis and platelet function, and multiple studies have
characterized sepsis coagulopathy by these tests [12-22]. The
endothelium plays a key role in balancing hemostasis [23-27],
and there is emerging evidence that endothelial activation
and damage are critical drivers of coagulopathy in acute cri-
tical illness, including severe sepsis [5,23-37].
Given that severe sepsis is associated with concurrent co-
agulopathy and endothelial disruption and damage, the aim
of the present study was to investigate the association be-
tween coagulopathy, evaluated by whole blood TEG, and
endothelial activation and/or damage in patients with se-
vere sepsis. We hypothesized that high levels of biomarkers
reflecting endothelial activation and/or damage would be
independently linked to concurrent whole blood TEG
hypocoagulability. In brief, the study confirmed our hypoth-
esis by demonstrating that single time-point measurements
of plasma markers of endothelial damage and, to a lesser
degree, endothelial activation, were independently associ-
ated with concurrent whole blood hypocoagulability by
TEG in patients with severe sepsis and septic shock. Clinic-
ally, endothelial protective interventions would be expected
to attenuate the sepsis-induced hypocoagulability.
Methods
Study patients
The present study is a sub-study of The Scandinavian
Starch for Severe Sepsis and Septic Shock (6S) trial [38],
restricted to patients enrolled from March 2010 to
November 2011 in two intensive care units (ICUs) at uni-
versity hospitals in Denmark (Rigshospitalet, Bispebjerg
Hospital). It was approved as a protocol amendment to
the 6S trial by the Ethics Committee of the Capital Region
of Denmark and the Danish Medicines Agency (Clinical-
trials.gov identifier: NCT00962156). Informed consent
was obtained from all participants or their legal substitute
prior to enrolment. The manuscript was prepared accord-
ing to the Strengthening the Reporting of Observational
studies in Epidemiology (STROBE) statement [39].The 6S trial was a multicenter, blinded clinical trial in
which ICU patients with severe sepsis were randomized to
fluid resuscitation with either 6% hydroxyethyl starch (HES)
130/0.42 in Ringer’s acetate (Tetraspan 6%, B Braun,
Melsungen, Germany) or Ringer’s acetate (Sterofundin ISO,
B Braun, Melsungen, Germany). Eligible patients fulfilled
the criteria for severe sepsis and needed fluid resuscitation
as judged by the treating clinician. Exclusion criteria
included renal replacement therapy (RRT), intracranial
bleeding or infusion of over 1,000 ml of synthetic colloids
at hospital admission, withdrawal and unobtainable con-
sent [38].
Among the 798 patients in the intention-to-treat popula-
tion [38], 226 patients were randomized at two ICUs that
collected and stored research blood samples as part of the
protocol after initiation of the present study (Rigshospitalet
and Bispebjerg Hospital). Eligible patients were patients
from these two ICUs who had concurrent pre-intervention
(baseline) thrombelastography (TEG) measurement and
endothelial biomarker measurements from baseline (data
on both syndecan-1 and thrombomodulin as a minimum
requirement), leaving 184 patients for analysis. Demog-
raphy, disease severity and mortality were comparable be-
tween the excluded and included patients (data not shown).
Previously published data from the study include the
primary results [38], as well as post-hoc analyses of the as-
sociation between vasopressor therapy and endothelial
damage in a subgroup of 67 patients randomized at two
university hospitals in Denmark [40]. A further analysis of
the association between consecutive TEG tracings and
clinical outcome in a subgroup of 260 patients random-
ized at four university hospitals in Denmark has also been
previously published [21].
Collection of clinical data
The following data were retrieved from the 6S trial database:
baseline patient demographics, co-morbidities, source of
sepsis (some patients had more than one source of infec-
tion), organ failures, disease severity scores (Simplified Acute
Physiology Score (SAPS) II and Sepsis-related Organ Failure
Assessment (SOFA) score without the cerebral component),
physiology and biochemistry, treatment with anti- and pro-
coagulant drugs, fluid balances, transfusion with blood prod-
ucts, and use of renal replacement therapy (RRT) and
mechanical ventilation. Follow-up data included date of dis-
charge from the ICU and date of death censored at one
year.
Routine biochemistry and hematology
Routine biochemistry variables were analyzed in a DS/EN
ISO 15189 standardized laboratory (hemoglobin, white
blood cell and platelet counts, creatinine, blood urea nitro-
gen (BUN), bilirubin, sodium and potassium), including
measurements of factor II-VII-X (FII-VII-X, Owren type
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plasma fibrinogen (p-fibrinogen) and D-dimer (ACL TOP).
Arterial blood gasses (ABG) and lactate were analyzed by
an ABL 725 (Radiometer, Copenhagen, Denmark).Thrombelastography and functional fibrinogen
Standard TEG (kaolin citrated TEG) and functional fi-
brinogen (tissue factor citrated FF) were performed at
time of inclusion (pre-randomization) in 3.2% citrated
whole blood using a TEG® 5000 Hemostasis Analyzer
System (Haemonetics Corp., MA, US). At both hospitals,
TEG and FF analyses were performed at the blood bank,
according to the manufacturer’s recommendations.
The TEG variables recorded were (normal range reported
by Haemonetics Corp.): reaction time (R (3 to 9 minutes),
rate of initial fibrin formation), angle (α (55 to 78 degrees),
clot growth kinetics, reflecting clot growth and the thrombin
burst), TEG maximum amplitude (TEG MA (51 to 69 mm),
reflecting maximum clot strength) and lysis after 30 minutes
(Ly30 (0 to 8%), proportional reduction in the amplitude 30
minutes after MA, reflecting fibrinolysis) [11]. The FF ana-
lysis included a platelet glycoprotein IIb/IIIa receptor inhibi-
tor. FF was performed to investigate the contribution from
fibrinogen to TEG MA (FF MA 14 to 27 mm).
The results of the TEG analyses were not made available
for the treating clinicians, but TEG analyses were routinely
used in the treatment of bleeding patients in the partici-
pating ICUs. Consequently, non-study TEG analyses and
interventions with plasma, platelets and hemostatic agents
based on non-study TEG results may have occurred in
some patients. The day-to-day coefficient of variation per-
centage of TEG MA is less than 7% in our laboratory [42].Enzyme-linked immunosorbent assay
Soluble endothelial-derived biomarkers were measured
by commercially available immunoassays in serum/
plasma, sampled pre-intervention (baseline), according to
the manufactures recommendations: syndecan-1 (Diaclone
SAS, Besancon, France; lower limit of detection (LLD) 4.94
ng/ml) and soluble thrombomodulin (sTM, Nordic Biosite,
Copenhagen, Denmark; LLD 0.31 ng/ml), both in serum;
protein C (PC, Helena Laboratories, Beaumont, TX, US;
relative quantification); tissue-type plasminogen activator
(tPA, Americal Diagnostics (ADI), detects single-chain (sc)-
tissue type plasminogen activator (tPA), two-chain (tc)-tPA
and tPA/PAI-1 complexes; LLD 1 ng/ml) and plasminogen
activator inhibitor-1 (PAI-1, Assaypro; LLD 0.07 ng/ml), all
in citrated plasma. The biomarkers measured were selected
to reflect distinct aspects of endothelial activation and
damage: glycocalyx damage (syndecan-1 [43]), endothelial
cell damage (soluble thrombomodulin (sTM) [44-46]),
endothelial cell activation (tPA and PAI-1 [47]) and pro-
tein C-induced natural anticoagulation [48].Statistics
Statistical analysis was performed using SAS 9.1.3 SP4
(SAS Institute Inc., Cary, NC, US).Simple correlations
were investigated by Pearson correlations, with results dis-
played as Pearson’s r, Pearson’s r2 (r2) and P values. To
investigate the independent association between endothe-
lial activation and damage (syndecan-1, thrombomodulin,
protein C, tPA and PAI-1) and coagulopathy evaluated by
TEG whole blood hemostasis (R-time, angle, TEG MA
and FF MA), univariate and backwards multivariate linear
regression analysis were performed, including variables
that were either found to correlate with or expected to in-
fluence TEG variables: SOFA score (encompasses assess-
ment of the ratio of partial pressure arterial oxygen and
fraction of inspired oxygen (PaO2/FiO2), mean arterial
blood pressure (MAP)/vasopressor requirement, bilirubin,
platelet count and creatinine), D-dimer, Owren type PT,
p-fibrinogen and crystalloid administration (the previous
24 hours before blood sampling). Individual backwards
multivariate linear regression models, including only uni-
variate significant variables, were applied for each investi-
gated biomarker (syndecan-1, thrombomodulin and protein
C). Results are presented as regression coefficients (β) with
95% confidence intervals (CI) and t and P values. The asso-
ciation between syndecan-1 quartile and TEG and FF vari-
ables were investigated by univariate linear regression
analysis, with syndecan-1 quartile as the explanatory vari-
able, with results displayed as regression coefficients (β) with
95% CIs and P values. The association between syndecan-1
quartile and presence of fibrinolysis (Ly30 > 0%, yes or no)
was investigated by the Cochran-Armitage Trend Test, with
results displayed as P values. Descriptive data are presented
as medians with interquartile ranges (IQR) or as n (propor-
tions). P values <0.05 were considered to be significant.
Results
Patients
The 184 patients included in the present study were ran-
domized at two different trial sites (n = 140 (76%) at Rig-
shospitalet, n = 44 (24%) at Bispebjerg Hospital). The
patients had a median age of 67 years, with 55% being
male (Table 1). The majority of patients presented with
pulmonary (60%) or abdominal (30%) focus of infection
and had septic shock (n = 156 (86%)). A total of 34% of
patients underwent emergency surgery before admission
and 20% had hematologic malignancy (Table 1). The me-
dian SOFA and SAPS II scores at inclusion were 8 and
56, respectively, and 7-day, 28-day, 90-day and 1-year
mortality rates were 21%, 39%, 53% and 61%, respect-
ively (Table 1). Data on endothelial-derived biomarkers
and TEG and FF are displayed in Table 1. Among the
184 patients, 23 (13%), 90 (49%) and 71 (39%) presented
with a hypocoagulable, normal and hypercoagulable
TEG MA, respectively, whereas 35 (19%), 94 (51%) and
Table 1 Baseline (inclusion) characteristics,
endothelial-derived biomarker levels,
thrombelastography, transfusions during ICU stay
and outcome in 184 patients with severe sepsis
All
Variable Median (IQR)
Age years 67 (59-75)
Male gender n (%) 101 (55%)
Disease severity
Lactate mmol/l 2.2 (1.4-3.7)
SBP mmHg 82 (70-92)
SOFA score 8 (6-10)
SAPS score 56 (41-68)
Biochemistry
Hemoglobin g/dl 9.5 (8.4-10.8)
White blood cells 109/l 12.3 (7.4-20.1)
Platelet count 109/l 133 (71-232)
Creatinine μmol/l 97 (62-172)
BUN μmol/l 10.5 (6.8-17.7)
Bilirubin μmol/l 12 (7-21)
D-dimer mg FEU/l 4.8 (2.2-9.6)
Owren type PT % 0.47 (0.34-0.61)
Plasma fibrinogen g/l 4.7 (3.4-6.5)
Endothelial biomarkers
Syndecan-1 ng/ml 97 (51-204)
Thrombomodulin ng/ml 7.7 (5.2-10.8)
Protein C % 47.4 (33.5-66.4)
tPA ng/ml 16.4 (11.4-23.6)
PAI ng/ml 30.9 (19.3-39.5)
Thrombelastography (TEG)
R-time min 7.7 (6.4-9.3)
Angle degrees 65 (55-71)
TEG MA mm 66 (58-72)
Ly30 % 0 (0.0-0.3)
Ly30 > 0% n (%) 65 (36%)
Functional fibrinogen (FF)
FF MA mm 21.9 (16.1-28.8)
Transfusions in ICU
RBC n (%) 119 (65%)
FFP n (%) 64 (35%)
Platelets n (%) 52 (28%)
Table 1 Baseline (inclusion) characteristics,
endothelial-derived biomarker levels,
thrombelastography, transfusions during ICU stay
and outcome in 184 patients with severe sepsis
(Continued)
Mortality
7-day n (%) 39 (21%)
28-day n (%) 72 (39%)
90-day n (%) 98 (53%)
1-year n (%) 113 (61%)
Data are presented as medians (IQR) or n (%). BUN, blood urea nitrogen;
Emergency surgery, emergency surgery prior to ICU admission; FF MA, maximum
amplitude in functional fibrinogen; FEU, fibrinogen equivalent units; FFP, fresh
frozen plasma; Ly30, lysis 30 minutes after MA; Mortality; mortality of any cause;
Owren type PT, reporting coagulation factor activity in percentage [41]; PAI-1,
plasminogen activator inhibitor-1; R-time, reaction time; RBC, red blood cells; SAPS,
simplified acute physiology score (calculated from 17 variables with higher scores
indicating more severe disease, but without recording the cerebral component of
the score); SBP, systolic blood pressure; SOFA, sequential organ failure assessment
(sub-scores ranging from 0 to 4 for each of five components (circulation, lungs,
liver, kidneys and coagulation, with aggregated scores ranging from 0 to 20, with
higher scores indicating more severe organ failure); TEG MA, maximum amplitude
in kaolin TEG; tPA, tissue-type plasminogen activator.
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coagulable FF MA. A comparable number of patients were
randomized into the two fluid intervention groups: 89 (48%)
were allocated to Ringer’s acetate and 95 (52%) to HES 130/0.42.
Clinical presentation and endothelial damage
Neither focus of infection nor presence of shock or emer-
gency surgery before admission influenced syndecan-1,
thrombomodulin or protein C quartiles (data not shown).
Patients with hematologic malignancy, however, were in a
high thrombomodulin quartile (P= 0.036), and patients with
shock at admission were in a higher tPA and PAI-1 quartile
(both P <0.01, data not shown).
Correlations and syndecan-1 quartiles
The TEG R-time, angle and MA all correlated weakly with
SOFA score (r = 0.27 (r2 0.07), r = −0.30 (r2 0.09), r = −0.34
(r2 0.12), respectively, all P <0.001), lactate (r = 0.18
(r2 0.03), r = −0.25 (r2 0.06), r = −0.32 (r2 0.11), respectively,
all P <0.05), platelet count (r = −0.35 (r2 0.13), r = 0.57
(r2 0.32), r = 0.69 (r2 0.48), respectively, all P <0.001), D-
dimer (r2 0.02, r2 0.03 and r2 0.04, respectively, Table 2, uni-
variate model) and Owren type PT (r2 0.03, r2 0.03 and r2
0.07, respectively Table 2, univariate model); TEG angle
and MA correlated with p-fibrinogen (r2 0.05 and r2 0.23,
respectively, Table 2, univariate model). Also, FF MA corre-
lated with platelet count (r2 0.07), D-dimer (r2 0.06), Owren
type PT (r2 0.17), p-fibrinogen (r2 0.67) and crystalloids ad-
ministered in the 24 hours prior to blood sampling and
randomization (r2 0.03) (all Table 2, univariate model).
TEG Ly30 correlated with SOFA score (r = 0.15 (r2 0.02),
P = 0.044) and lactate (r = −0.42 (r2 0.18), P <0.001).
Table 2 Univariate and backwards multivariate linear regression analyses of associations between coagulopathy
evaluated by TEG and biomarkers of endothelial activation and damage in 184 patients with severe sepsis
Variable Unit TEG R-time TEG Angle TEG MA FF MA
β (SE) t P β (SE) t P β (SE) t P β (SE) t P
Univariate
Syndecan-1 100 ng/ml 0.82 (0.24) 3 0.001 −3.06 (091) 3 0.001 −3.40 (0.79) −4 <0.001 −2.00 (0.64) −3 0.002
Thrombomodulin ng/ml 0.13 (0.06) 2 0.021 −0.49 (0.22) −2 0.026 −0.60 (0.19) −3 0.002 −0.58 (0.15) −4 <0.001
Protein C 10% −0.20 (0.10) −2 0.044 1.09 (0.37) 3 0.004 1.49 (0.32) 5 <0.001 1.05 (0.25) 4 <0.001
SOFA score point 0.30 (0.08) 4 <0.001 −1.25 (0.30) −4 <0.0001 −1.27 (0.26) −5 <0.001 - - NS
D-dimer mg FEU/l 0.03 (0.02) 2 0.044 −0.13 (0.06) −2 0.026 −0.13 (0.05) −3 0.011 −0.14 (0.04) −4 0.001
Owren type PT 10% −0.29 (0.12) −2 0.020 1.02 (0.46) 2 0.029 1.39 (0.40) 4 0.001 1.80 (0.30) 6 <0.001
P-fibrinogen g/l - - NS 1.41 (0.47) 3 0.003 2.62 (0.35) 7 <0.001 3.50 (0.18) 19 <0.001
Crystalloid 100 ml - - NS - - NS - - NS −0.10 (0.04) −2 0.022
Multivariate
Syndecan-1 100 ng/ml 0.64 (0.25) 3 0.013 - - NS −1.78 (0.87) −2 0.042 −0.84 (0.42) −2 0.045
SOFA score point 0.23 (0.08) 3 0.006 −1.19 (0.30) −4 <0.001 −1.07 (0.27) −4 <0.001 Not included
D-dimer mg FEU/l - - NS - - NS - - NS - - NS
Owren type PT 10% - - NS - - NS 0.96 (0.40) 2 0.020 0.86 (0.23) 3 0.001
P-fibrinogen g/l Not included 1.26 (0.44) 3 0.004 - - NS 3.44 (0.21) 17 <0.001
Crystalloid 100 ml Not included Not included Not included - - NS
Multivariate
Thrombomodulin ng/ml - - NS - - NS - - NS - - NS
SOFA score point 0.28 (0.08) 2 <0.001 −1.19 (0.30) −4 <0.001 −1.24 (0.26) −5 <0.001 Not included
D-dimer mg FEU/l - - NS - - NS - - NS - - NS
Owren type PT 10% −0.26 (0.12) −2 0.031 - - NS 1.27 (0.38) 3 <0.001 0.54 (0.20) 3 0.007
P-fibrinogen g/l Not included 1.26 (0.44) 3 0.004 - - NS 3.35 (0.21) 17 <0.001
Crystalloid 100 ml Not included Not included Not included - - NS
Multivariate
Protein C 10% - - NS - - NS 1.24 (0.31) 4 <0.001 - - NS
SOFA score point 0.28 (0.08) 4 <0.001 −1.19 (0.30) −4 <0.001 −1.09 (0.26) −4 <0.001 Not included
D-dimer mg FEU/l - - NS - - NS - - NS - - NS
Owren type PT 10% −0.26 (0.19) −2 0.031 - - NS - - NS 0.54 (0.20) 3 0.007
P-fibrinogen g/l Not included 1.26 (0.44) 3 0.004 - - NS 3.35 (0.21) 17 <0.001
Crystalloid 100 ml Not included Not included Not included - - NS
Regression coefficients (β) with standard errors (SE), t and P values displayed for the univariate and backwards selection multivariate models. Individual backwards
multivariate linear regression models including only univariate significant variables, were applied for each investigated biomarker (syndecan-1, sTM and protein C).
P values are shown in bold for endothelial-derived biomarkers with P <0.05. Predicted change in TEG R-time (minutes), TEG angle (degrees),TEG MA (maximum
amplitude, mm) or FF MA (maximum amplitude, mm) associated with one unit increase in syndecan-1 (100 ng/ml), thrombomodulin (ng/ml), protein C (10%),
SOFA score (point), D-dimer (mg FEU/l), Owren type PT (10%), plasma (p)-fibrinogen (g/l) and crystalloids administered in the 24 hours prior to blood sampling
and randomization (100 ml).
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blood sampling and randomization neither correlated with
TEG and FF nor with endothelial biomarkers (data not
shown). TEG and FF variables all correlated with syndecan-1,
thrombomodulin and protein C (Table 2, univariate model).
Furthermore, PAI-1 correlated with TEG MA (r =−0.20
(r2 0.04), P= 0.006) and FF MA (r =−0.37 (r2 0.13),
P <0.001). Also, increasing disseminated intravascular
coagulation (DIC) score was associated with increasedsyndecan-1 (P <0.001) and thrombomodulin (P <0.001)
and reduced protein C (P <0.001), whereas tPA and PAI-1
remained stable across DIC scores (data not shown).
In accordance with the correlations, higher syndecan-1
quartile was associated with TEG and FF hypocoagul-
ability, evidenced by increased R-time and reduced
angle, TEG and FF MA (Figure 1A-D), whereas it was
associated with a reduced proportion of patients pre-
senting with TEG fibrinolysis (Figure 1E).
Figure 1 Thrombelastography (TEG) and functional fibrinogen (FF) variables in 184 patients with severe sepsis stratified according to plasma
syndecan-1 quartiles. The median and interquartile ranges (A-D) or proportions (C) are shown for: A) TEG reaction time (R-time; minutes), B) TEG
angle (degrees), C) TEG maximum clot strength (MA; mm), D) FF MA (mm) and E) Ly30 > 0% (proportion). The influence of syndecan-1 quartile in
Figure 1A-D on TEG and FF variables were investigated by linear regression analysis with syndecan-1 quartile as the explanatory variable, with
results displayed as regression coefficients (β) with 95% confidence intervals and P values. Presence of fibrinolysis (Ly30 > 0%) across syndecan-1
quartiles in Figure 1E was investigated by Cochran-Armitage Trend Test, with results displayed as P values.
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blood coagulopathy and endothelial activation and damage
The independent association at one time-point between
coagulopathy and endothelial activation and damage was
investigated by linear regression with individual backwards
multivariate linear regression models, including only uni-
variate significant variable applied for each investigated
biomarker (syndecan-1, thrombomodulin and protein C)
(Table 2).
In the univariate analyses, higher SOFA score and D-
dimer, but lower Owren type PT and p-fibrinogen, were
associated overall with more hypocoagulable TEG and
FF profiles, corresponding to increased R-time and re-
duced angle, TEG MA and TEG FF (Table 2). Similarly,
higher syndecan-1 and sTM and lower protein C were
associated with more hypocoagulable TEG and FF
profiles in the univariate analyses. Higher PAI-1 was as-
sociated with a more hypocoagulable TEG MA (β: −0.20
mm (95% CI: −0.34 to −0.06), P = 0.006) and FF MA
(β: −0.29 mm (95% CI: −0.40 to −0.18), P <0.001),
whereas tPA was neither associated with TEG nor FF
variables (data not shown).
In the multivariate analyses including the univariate
significant variables and either syndecan-1, thrombomo-
dulin or protein C, higher syndecan-1 was independ-
ently associated with TEG and FF hypocoagulability,
evidenced by increased R-time and reduced TEG MA
and FF MA (Table 2). Also, lower protein C was associ-
ated with reduced TEG MA (Table 2), whereas PAI-1
and tPA were not independently associated with TEG or
FF MA (data not shown). In addition to syndecan-1 and
protein C, higher SOFA score was consistently inde-
pendently associated with TEG and FF hypocoagulabil-
ity (Table 2), whereas lower Owren type PT and p-
fibrinogen were independently associated with TEG and
FF hypocoagulability in some multivariate analyses
(Table 2).Discussion
The main finding of the present study was that plasma
markers of endothelial damage and, to a lesser degree,
endothelial activation, were independently associated with
concurrent whole blood hypocoagulability by TEG in
patients with severe sepsis and septic shock. Furthermore,
fibrinolysis was inversely associated with syndecan-1 quar-
tiles, suggesting a negative influence of glycocalyx damage
on fibrinolysis.
The vascular endothelium influences hemostasis,
locally or systemically, through controlled release, ex-
pression and/or support of systems and/or elements that
either promote or inhibit coagulation [23-27]. There is
emerging evidence that the endothelium, actively or
passively, contributes to coagulopathy in acute critical
illness, including sepsis [5,23-26,28-37,49]. The endothe-
lium comprises a single layer of cells that lines the inner
of all blood vessels and traverses all organs in the body,
establishing a unique interface between the underlying
tissue and flowing blood [25]. The luminal surface of the
endothelial cells is covered by the glycocalyx that binds
and incorporates soluble molecules derived from the
plasma and endothelium, with the highest amounts of
plasma-derived constituents towards the luminal surface
[50]. It provides the endothelium with an anti-adhesive
and anticoagulant surface that protects the underlying
endothelial cells and contributes to control of vascular
barrier function [51-53].
Glycocalyx damage, evidenced by increased levels of cir-
culating syndecan-1 [43], can range from discrete distur-
bances in the composition of the most luminal layer, to
excessive destruction and degradation, with loss of the en-
tire glycocalyx [50,51]. Clinically, glycocalyx and endothelial
cell damage are associated with pathophysiologic sequels
like capillary leakage and tissue edema, accelerated inflam-
mation and platelet activation, microvascular thrombus
formation, loss of vascular responsiveness, hypotension,
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[6,51,52,54,55].
Importantly, upon shedding, the glycocalyx constituents
retain their anticoagulant heparin-like activity [49] and pro-
mote measurable TEG hypocoagulability in the flowing
blood through endogenous heparinization, as demonstrated
in hepatic failure, severe sepsis [31,32,49] and trauma [35].
This may mechanistically explain part of the association be-
tween syndecan-1 and TEG hypocoagulability observed in
the present study. Also, the association between lower
protein C levels and TEG hypocoagulability may be attrib-
uted to enhanced protein C activation, and consequently
increased endogenous anticoagulation, due to inactivation
of factors V and VIII and induction of hyperfibrinolysis
[56-59]. Together, these findings suggest that endothelial
damage, and to a lesser degree activation, may be linked to
functional whole blood hypocoagulability in severe sepsis.
Clinically, endothelial protective interventions would
hereby be expected to attenuate the sepsis-induced hypo-
coagulability. However, given the relatively weak correla-
tions between endothelial activation and damage markers
and TEG/FF variables, as evaluated by the coefficients of
determination (r2), it should be emphasized that factors be-
sides the endothelium may also contribute significantly to
the observed hypocoagulability. Also, the observational na-
ture of the study makes it impossible to establish causality,
meaning that the association between endothelial damage
and TEG hypocoagulability could also be attributed to co-
agulation factor and platelet consumption due to micro-
thrombi formation.
Acute critically ill patients suffering from non-septic
disease, such as severe trauma and resuscitated cardiac
arrest, also display evidence of excessive endothelial ac-
tivation and damage concurrent with coagulopathy
[28,29,60-67]. We recently proposed that the coagulopa-
thy observed in severe trauma and other types of acute
critical illness reflects a universal response mounted to
counterbalance emerging systemic microvascular and
endothelial disruption and damage inflicted by the ‘in-
jurious hit’, that is, the tissue injury, infection and/or
ischemia-reperfusion injury and its concurrent activa-
tion of the neurohumoral, inflammatory and hemostatic
systems [37]. Recent studies of trauma, sepsis and burn
patients support the notion that different injurious hits
generate a common genetic response [68,69]. Conse-
quently, we infer that the coagulopathy observed in
acute critically ill and shocked patients may reflect that
evolution has prioritized a response that ensures oxygen
supply above hemostasis in these patients [37].
In the present study, excessive glycocalyx damage (ev-
idenced indirectly by high circulating syndecan-1 levels)
was inversely associated with functional TEG hyperfibri-
nolysis. Though excessive hyperfibrinolysis represents
an extreme form of coagulopathy observed in somecritically ill and shocked patients suffering from, for ex-
ample, severe trauma [70-75], resuscitated cardiac arrest
[36,76-78] and septic shock [15], the ‘fibrinolytic shut-
down’ and enhanced thrombus generation in severe sep-
sis may limit pathogen dissemination but drive organ
failure [9,10,79-81]. Thus, the inverse correlation be-
tween Ly30 and syndecan-1 may suggest that ‘physio-
logic’ fibrinolysis is an active endothelial process that
may be impaired by excessive endothelial activation and
glycocalyx degradation.
The results presented here are subject to several limi-
tations. First, the observational nature of the study does
not allow independent evaluation of the cause-and-
effect relationship suggested, as mentioned above. Sec-
ond, as this was a sub-study to the 6S trial, some of the
exclusion criteria may not be entirely relevant for the
present study, which may reduce the generalizability of
the results. Third, we did not adjust for multiple testing,
emphasizing that results obtained from a post-hoc sub-
group study such as in this study, should be interpreted
with caution and optimally confirmed in later studies
designed specifically for that purpose. Fourth, the data
presented here were based on single time-point mea-
surements and not consecutive data. To establish the
potential causality and improve our understanding of
the interaction between the two extremely complex
biologic systems (the endothelium and hemostasis) in
patients with complex diseases like sepsis, prospective
randomized studies are warranted, investigating hemostasis
in patients treated with intervention(s) expected to protect
the endothelium.
Conclusions
We found that a single time-point measurement of plasma
markers of endothelial damage and, to a lesser degree,
endothelial activation, were independently associated with
whole blood hypocoagulability by TEG in patients with se-
vere sepsis, and that fibrinolysis correlated inversely with
markers of glycocalyx damage. These findings suggest that
endothelial activation and damage may be linked to hypo-
coagulability in patients with severe sepsis.
Key messages
 A single time-point measurement of plasma markers of
endothelial damage and, to a lesser degree, endothelial
activation, were independently associated with whole
blood hypocoagulability by TEG in patients with severe
sepsis and septic shock.
 Fibrinolysis was inversely associated with syndecan-
1, a marker of glycocalyx damage.
 These findings suggest that endothelial activation
and damage may be linked to hypocoagulability in
patients with severe sepsis.
Ostrowski et al. Critical Care  (2015) 19:191 Page 8 of 10 Clinically, endothelial protective interventions would
be expected to attenuate sepsis-induced
hypocoagulability.
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